Uniqure NV
NASDAQ:QURE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Omnicom Group Inc
NYSE:OMC
|
US |
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
UK |
Uniqure NV
EPS (Diluted)
Uniqure NV
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Uniqure NV
NASDAQ:QURE
|
EPS (Diluted)
-$3
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
Pharming Group NV
AEX:PHARM
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
EPS (Diluted)
€0
|
CAGR 3-Years
24%
|
CAGR 5-Years
16%
|
CAGR 10-Years
8%
|
|
|
argenx SE
XBRU:ARGX
|
EPS (Diluted)
$19
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
EPS (Diluted)
-$5
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-11%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
EPS (Diluted)
$0
|
CAGR 3-Years
26%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
Uniqure NV
Glance View
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
See Also
What is Uniqure NV's EPS (Diluted)?
EPS (Diluted)
-3.5
USD
Based on the financial report for Dec 31, 2025, Uniqure NV's EPS (Diluted) amounts to -3.5 USD.
What is Uniqure NV's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
1%
Over the last year, the EPS (Diluted) growth was 30%. The average annual EPS (Diluted) growth rates for Uniqure NV have been -8% over the past three years , -4% over the past five years , and 1% over the past ten years .
